Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.
Ulcerative Colitis(UC)
Abivax – ABX464
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis.
Janssen Astro
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Nonalcoholic Steatohepatitis (NASH)
Inventiva
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3.
Novo Nordisk
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
Crohn’s
Arena(cultivate)
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.
Screening Colonoscopy
Guardant Eclipse
The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer. No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.
Guardant Almanac
The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer.
Pill Cam Data Collection
SB3 PillCam (SODA)
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
